2Morrow Launches New Digital Therapeutic Aimed at Managing Chronic Pain with a Non-Opioid, Behavioral Approach | 2Morrow
VA Awards Magnolia Medical Technologies Contract for Blood Collection Device | Magnolia Medical
Cardea 20/20 ECG helping provide in-dept heart testing to student athletes | KPRC2
Product Creation Studio Promotes Sonja Takatori To Director Of Program Management | Product Creation Studio
Cyrus Bio Co-Founder David Baker Featured in the New York Times | Cyrus Biotechnology
Cardiac Insight gets first customers for its wearable heart-monitoring device | Puget Sound Business Journal
Cyrus Bio Leads Computational Protein Engineering Panel | Cyrus Biotechnology
DEPARTMENT OF COMMERCE INVITES PIA TO JOIN GACC CLUSTER INITIATIVE | PIA Medical News
Seed Funding Slows in Silicon Valley | The New York Times
MedTech Innovator Announces Startups Selected for Industry’s Premier Accelerator | MedTech Innovator
Cardiac INSIGHT: Upending the Mobile Cardiac Monitoring Business | The MedTech Strategist
UNMC study shows billions can be saved by reducing blood draw contamination | Magnolia Medical
SGMC REHAB FIRST IN GEORGIA TO OFFER KICKSTART DEVICE | Valdosta Today
MAGNOLIA MEDICAL APPOINTS ROBERT E. GERBERICH AS CHIEF COMMERCIAL OFFICER | Magnolia Medical
Cardiac Insight Announces FDA Clearance of “CARDEA SOLO™” | Business Wire
PIA Announces new VP: Christian Teague | PIA News
Monitor Mask has finalized an OEM distribution agreement with Salter Labs. The CapnoVue face masks are now listed on two GPO contracts. Monitor Mask welcomed Mark Strmac as the Eastern Regional Sales Director and engaged the services of Sherrill Small as a marketing consultant.
2Morrow Inc. Wins MedTech Innovator Seattle Pitch | Life Science Washington Member News
IMPEL NEUROPHARMA EXPANDS PATENT PORTFOLIO | Impel Neuropharma
VETERAN BIOTECH EXECUTIVE TIMOTHY S. NELSON JOINS IMPEL’S BOARD OF DIRECTORS | Impel NeuroPharma
WINGS and MedTech Innovator, sponsored in part by Life Science Washington will be holding a pitch competition March 15 in Seattle at the Agora Conference Center. Also, Bill Waller gives an update about WINGS Winners at AdvaMed’s 2016 Innovation Showcase.
OtoNexus raises $8m for middle-ear infection tech | Mass Device
WINGS and MedTech Innovator, sponsored in part by Life Science Washington, will be holding a pitch competition March 15, 2017 at the Agora Conference Center located at 1551 Eastlake Ave E.
MedTech Innovator is the industry’s nonprofit global competition and accelerator. In 2017, MedTech Innovator will award over $500K in cash prizes. Early to mid-stage medical device, diagnostic, and digital health companies are encouraged to apply at https://medtechinnovator.org/apply by the Feb. 28 deadline.
Cyrus Biotechnology supports the Boston Area Group for Informatics and Modeling | Cyrus Biotechnology
Cyrus Biotechnology CEO to Unveil Cyrus Bench software for Protein Modeling and Design | Cyrus Biotechnology
Seattle’s $1 billion biotech brothers: Inside Adaptive Biotechnologies | Puget Sound Business Journal
Austin startup investor group with millions on hand restructures to do more deals | Austin Business Journal
Cardiac Insight raises $2M for heart-monitoring devices | Puget Sound Business Journal
Accelerating BioPharma with powerful software tools on the cloud.
Adaptive Biotechnologies – Seattle’s stealthy biotech unicorn – expands in redesigned HQ | Puget Sound Business Journal
Concurrent documentation in mental health | Valant Blog
Simple digital technologies can reduce healthcare costs | Harvard Business Review
Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma. Results from these new innovative clinical tools can help inform treatment decisions for active symptomatic patients as well as those undergoing maintenance treatment. | Adaptive Biotechnologies
A paper from Harvard Business School/MIT Sloan School of Management finds that startups funded by angel investors are more likely to survive the first few years. Angel funding also affected the likelihood of a successful exits for the companies studied. | Third Way
2Morrow takes 2nd place at the Cascadia Venture Forum | Cascadia Venture Forum
2Morrow named one of 15 finalists of MedCity’s patient engagement startup contest. A reader’s choice winner will be selected via poll. Separately, a judging panel will select winners. These results will be announced later in October. | MedCity News
Cyrus co-founder Yifan Song is a co-author on a new manuscript using Rosetta to automatically build atomic resolution models of complex protein assemblies from cryo-EM data. Publication can be found at elifesciences.org | Cyrus Biotechnology
3 steps to find and close Angel investors by David Beisel | NextView Ventures Blog
Cyrus co-founder Yifan Song is a co-author on a Nature manuscript detailing combined computational and wet lab work methods to design cycle peptides. Publication can be found at www.nature.com | Cyrus Biotechnology
Adaptive Biotechnologies has added open-access to over 37 million unique B-cell Receptor (BCR) sequences from health adult donors. This data was also published in PLOS ONE: A Public Database of Memory and Naive B-Cell Receptor Sequences | Adaptive Biotechnologies
H-Source was recently listed on the Toronto Stock Exchange. They have 200+ hospitals under contract with 150 on-boarded, and are on track to have 350+ by year end. They have four prominent mutual funds among their investors and they are creating value for hospitals as well as good jobs in Eastern Washington. | H-Source
Seattle medical device company, OtoNexus, on a 4-year path to acquisition | Puget Sound Business Journal
Cardiac Insight raises $2.5M to fund sales push for CardeaScreen.
Chad Robins, CEO Adaptive Technologies, was selected as a finalist for the EY Entrepreneur Of The Year® 2016 Award in the Pacific Northwest.
Impel NeuroPharma was awarded a $1.5M Phase II SBIR Grant from NIMH to further develop pre-clinical POD devices.
Cyrus Biotechnology is turning Rosetta into a commercial-grade, cloud computing platform. David Baker presented at the EXOME Life Science Disruptors conference by Xconomy.
2Morrow raises $500k to grow user base.
Seattle-based PotaVida, which designs bags that purify water with sunlight and collect data on how the bag is used, will have a big test in mid-May.
Dr. Jonathan Bricker, Fred Hutchinson Cancer Research Center, has teamed up with Dr. Feng Cheng, Tsinghua University in Beijing, to develop Smart Quit China.
OtoNexus was selected as the InnovateHer Seattle 2016 winner out of 8 finalists. OtoNexus was awarded $5k of developer services provided by Mr. PK Samal of Startup Fair.
In a twist on the traditional smoking cessation model, GlaxoSmithKline ($GSK) is pairing with 2morrow’s SmartQuit app to supply patches to smokers who have already completed the app plan.
Adaptive Biotechnologies announces Diego Miralle as the president of the new division: Adaptive Therapeutics.
The Microsoft co-founder announced Friday that he would issue two grants, worth more than $2 million, focused on the current Zika outbreak spreading around the world, which is suspected to be the cause of a growing number of birth defects in Brazil. (Read more about research going on in Seattle here).
H-Source is now trading under the symbol HSCHF on the OTCQB in the United States of America.
Valant Medical Solution’s Valant Platform featured as a mental health technology tool to help receive facilities funding.
Centurion Medical Products has acquired NuvoMed, Inc. and the DisImpactor (R).
PIA adds toSense and Erasmus University to their Core Lab business.
JW Beard, CTO of Monitor Mask, and Brandon Masterson, CEO of 2Morrow, were celebrated at the 2015 Seattle Health Innovators award ceremony as Seattle Health Innovators.
Monitor Mask completed the initial close for its Series A funding round.
Cyrus Biotechnology licenses biochemistry software to Indiana University Research and Technology Corporation (IURTC) at Indiana University to commercialize SparksX software.
Monitor Mask, Inc. has released the FDA-cleared CapnoVue M1 face mask for improved CO2 monitoring. This mask will provide reliable and consistent CO2 monitoring during sedation anesthesia.
FHCRC scientist Jonathan Bricker awarded 5 year, $3.1M grant from the National Cancer Institute to update SmartQuit.
Cyrus Biotechnology’s SaaS product, Cyrus Bench, can rapidly sort millions of virtual proteins to help speed up drug design.
More than three years later, entrepreneurs are still waiting for federal regulators to finish drafting the long-overdue rules that would let that part of the law take effect. Now, state agencies and lawmakers, tired of waiting, are taking action, passing crowdfunding laws and regulations to let local businesses raise money from local residents.
Cyrus Biotechnology is excited to announce their licensing of Rosetta software from the University of Washington and their initial funding.
With support from the Life Sciences Discovery Fund (LSDF), SmartQuit is starting its second clinical trial to evaluate effectiveness among employers.
The Alliance of Angels, one of the longest running angel investment groups in the Pacific Northwest, has raised a new $5.3 million seed fund that it will use to bankroll a new group of startup entrepreneurs. Backers of the fund include Madrona Venture Group, Trilogy Equity Partners and Voyager Capital, as well as angel investors such as Geoff Entress, Linden Rhoads, Michael Schutzler and Steve Singh.
2Morrow’s SmartQuit was pitted again NCI’s QuitGuide app in a double-blind randomized study. SmartQuit users were found to open the app more. SmartQuit users had a 13% quit rate compared to 8% for QuitGuide.
The M1 Capnography Mask by Monitor Mask Inc., has obtained US FDA 510(k) premarket notification clearance.
2Morrow announces licensing agreement with the Fred Hutchinson Cancer Research Center to commercialization The SmartQuit app.
2Morrow awarded $250k grant from LSDF for smoking cessation app.